Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma

Journal of Oncology Pharmacy Practice

Volumn 23, Issue 1, 2017, Pages 71-74

  Laporte, Justin ^a   Solh, Melhem ^b   Ouanounou, Serge ^a  

^a NORTHSIDE HOSPITAL   (United States)

^b Blood and Marrow Transplant Group of Georgia   (United States)

Author keywords

encephalopathy syndrome; Hodgkin; Keytruda; pembrolizumab; posterior reversible; PRES

Indexed keywords

BRENTUXIMAB VEDOTIN; IPILIMUMAB; LACOSAMIDE; NIVOLUMAB; PEMBROLIZUMAB; RAPAMYCIN; VORINOSTAT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMMON BILE DUCT STONE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; TONIC CLONIC SEIZURE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HODGKIN DISEASE; HUMANS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 85006374998     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215620922     Document Type: Article

References (11)

1. Thompson RJ, Sharp B, Pothof J, et al. Posterior reversible encephalopathy syndrome in the emergency department: case series and literature review. West J Emerg Med 2015; 15: 5-10.
2. Stevens CJ, Heran MKS,. The many faces of posterior reversible encephalopathy syndrome. Br J Radiol 2012; 85: 1566-1575.
3. Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES): features on CT and MR imaging. Diagn Interv Imaging 2013; 94: 45-52.
4. Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30: e76-e78.
5. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc 2010; 85: 427-432.
6. Pruitt AA, Graus F, Rosenfeld MR,. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurohospitalist 2013; 3: 24-38.
7. Moskowitz CH, Ribrag V, Michot J, et al. PD-1 Blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b Study; (Abstract #290). In: The 56th annual meeting of the American Society of Hematology, San Francisco, CA, 8 December 2014.
8. KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ; Merck; Revised January, 2015.
9. Bryan LJ, Gordon LI,. Blocking tumor escape in hematological malignancies: the anti-PD-1 strategy. Blood Rev 2015; 29: 25-32.
10. Peng W, Liu C, Xu C, et al. PD-1 Blockade enhances T cell migration to tumors by elevating IFN-3 inducible chemokines. Cancer Res 2012; 72: 5209-5218.
11. Kofler J, Bartynski WS, Reynolds TQ, et al. Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy. J Comput Assist Tomogr 2011; 35: 39-42.